Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 2007;116:419-426
Published online before print July 9, 2007, doi: 10.1161/CIRCULATIONAHA.106.673319
CLINICAL PERSPECTIVE
Free Article
This Article
Free upon publication Free Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/4/419    most recent
CIRCULATIONAHA.106.673319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pieretti, J.
Right arrow Articles by Salmon, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pieretti, J.
Right arrow Articles by Salmon, J. E.
Related Collections
Right arrow Hypertrophy
Right arrow Echocardiography

(Circulation. 2007;116:419-426.)
© 2007 American Heart Association, Inc.

Vascular Medicine

Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass

Janice Pieretti, MD; Mary J. Roman, MD; Richard B. Devereux, MD; Michael D. Lockshin, MD; Mary K. Crow, MD; Stephen A. Paget, MD; Joseph E. Schwartz, PhD; Lisa Sammaritano, MD; Daniel M. Levine, PhD; Jane E. Salmon, MD

From the Divisions of Cardiology (J.P., M.J.R., R.B.D.) and Rheumatology (M.D.L., M.K.C., S.A.P., L.S., J.E.S.) and the Rogosin Institute (D.M.L.), Weill Medical College of Cornell University and the Hospital for Special Surgery, New York, NY; and Department of Psychiatry (J.E.S.), SUNY-Stony Brook, Stony Brook, NY.

Correspondence to Mary J. Roman, Division of Cardiology, 525 E 68th St, New York, NY 10021. E-mail mroman{at}med.cornell.edu

Received October 31, 2006; accepted June 1, 2007.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Background— Systemic lupus erythematosus (SLE) is associated with premature atherosclerosis and vascular stiffening. Whether SLE alters left ventricular (LV) structure and function in the absence of valvular and clinical coronary artery disease is unknown.

Methods and Results— SLE patients without clinical or echocardiographic evidence of valvular or coronary disease were age and gender matched to a reference group (n=173 in both groups). Subjects underwent echocardiography to quantify LV structure and function and carotid ultrasonography to detect atherosclerosis. Disease characteristics and radial applanation tonometry to measure arterial stiffness were evaluated in SLE patients. The 2 groups were similar in subjects’ body size, hypertension and diabetes status, smoking status, and cholesterol levels. LV mass (38.3 versus 32.8 g/m2.7), ejection fraction (71% versus 67%), and prevalence of LV hypertrophy (17.9% versus 6.4%) were higher in SLE patients than in referent subjects (all P<0.001). The combination of SLE and hypertension further increased LV mass. In multivariable analysis, LV mass was associated with SLE (P<0.001) in addition to body mass index, diabetes mellitus, and hypertension. Among SLE patients, LV mass was associated with arterial stiffness (P<0.001). Carotid atherosclerosis, SLE duration, damage index, serum creatinine, and homocysteine were significantly related to LV mass in univariate but not multivariable analyses.

Conclusions— SLE predicts increased LV mass, possibly because of inflammation-related arterial stiffening. Excess LV hypertrophy may contribute to the increased cardiac morbidity and mortality observed in SLE patients.


Key Words: echocardiography • hypertrophy • inflammation • lupus erythematosus, systemic • ventricles


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Alterations in left ventricular (LV) structure and function have been reported among the cardiac manifestations of systemic lupus erythematosus (SLE),1–6 including echocardiographic evidence of increases in LV wall thicknesses and mass, a decrease in LV ejection fraction, and impaired diastolic filling. However, the extent to which these findings might be due to renal disease or other concomitant cardiovascular disease, including hypertension, valvular heart disease, or coronary artery disease, has not been fully elucidated. Thus, it is currently uncertain whether abnormalities of LV structure and function in SLE are disease-related effects or are a result of other predisposing conditions.

Mechanisms by which SLE might directly induce changes in LV structure include underlying inflammatory processes leading to subclinical vasculitis, myocarditis, or vascular stiffening. Since the advent of corticosteroid therapy, vasculitis and myocarditis are rare findings in SLE patients who undergo autopsy.7–9 In contrast, we recently documented marked increases in arterial stiffness in SLE patients compared with control subjects, a finding that was directly related to chronicity of disease and circulating markers of inflammation.10 Ventricular remodeling and subsequent hypertrophy may therefore result from increased inflammation-mediated vascular stiffness. In addition, preclinical coronary artery disease also may be a contributing factor to LV structural changes, given the premature development of atherosclerosis in SLE patients.11,12

Clinical Perspective p 426

In the present study, we compared SLE patients with a reference group to evaluate the prevalence of LV hypertrophy in SLE patients and to determine whether this was a consequence of traditional stimuli or related to aspects of the disease (serological markers, inflammatory mediators, treatment, premature atherosclerosis). To eliminate confounding aspects of earlier studies, we specifically excluded SLE patients with renal failure and clinical or echocardiographic evidence of significant valvular or coronary heart disease. We hypothesized that LV hypertrophy would be more prevalent and that such hypertrophy could result from increased vascular stiffness or from premature generalized atherosclerosis.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Study Design
A total of 203 patients with SLE were consecutively recruited from the Autoimmune Disease Registry at the Hospital for Special Surgery at the time of outpatient visits. All patients met the diagnostic criteria of the American College of Rheumatology.13 Exclusion criteria included pregnancy, renal failure (serum creatinine ≥3.0 mg/dL and/or creatinine clearance ≤30 mL/min), evidence of clinical coronary artery disease, and echocardiographic evidence of segmental wall motion abnormalities or greater than mild aortic or mitral valve disease. Fifteen patients were excluded on the basis of significant valvular disease alone (10 patients had mitral regurgitation, 4 had aortic regurgitation, and 1 had both). Clinical coronary artery disease was found in 8 patients, 2 with myocardial infarction (documented by segmental wall motion abnormalities) and 6 with angina (confirmed by abnormal coronary angiography in 5 and abnormal perfusion scan in 1). Two of the patients with coronary artery disease also had overlapping valvular disease. Patients were matched to referent subjects on the basis of age (within 5 years) and gender. Referent subjects were drawn from normotensive and hypertensive subjects participating in National Institutes of Health–funded studies using similar imaging protocols and performed at Cornell University.14,15 None of the referent subjects had clinical coronary artery disease or significant valvular disease. A total of 6 patients could not be matched to suitable referent subjects. Finally, 1 patient was excluded because of a lack of LV mass data on echocardiography.

Cardiovascular risk factors, including serum lipids, smoking history, body mass index, and the presence or absence of diabetes mellitus and hypertension (defined by a blood pressure of at least 140/90 mm Hg or the use of antihypertensive medications), were assessed in all subjects. Antihypertensive medications were systematically withdrawn at least 3 weeks before study in the hypertensive referent subjects but not in hypertensive SLE patients (38 SLE patients were taking antihypertensive medications at the time of study). Comprehensive medical histories of SLE patients were obtained via interview and chart review using a standardized data collection instrument. Disease activity and disease-related damage were assessed with the use of the Systemic Lupus Erythematosus Disease Activity Index16 and the Systemic Lupus International Collaborating Clinics Damage Index,17 respectively. Medication records were obtained that included use of prednisone, azathioprine, cyclophosphamide, and methotrexate. Serological markers of SLE, including inflammatory mediators and specific antibodies, were obtained using standardized laboratory assays. The study protocol was reviewed by the institutional review board, and all participants gave written informed consent.

Ultrasonographic Studies
Echocardiography was performed by an experienced research technician using standard techniques and interpreted by a single cardiologist who was unaware of the clinical characteristics of the patients and referent subjects. Measurements of LV dimensions and reference limits for LV mass were made according to American Society of Echocardiography recommendations.18 LV mass (LVM) was calculated using the following formula: LVM=0.8 {1.04[(LVIDd+PWTd+SWTd)3–(LVIDd)3]}+0.6 g, where LVID is LV internal dimension, PWT is posterior wall thickness, SWT is septal wall thickness, and subscript d represents end diastole. LV mass was indexed for either body surface area or the power of its allometric or growth relation with height (height2.7). This latter method of indexation of LV mass allows better detection of hypertrophy that is related to obesity and improves prediction of cardiovascular risk.19,20 LV hypertrophy was considered present if the mass index exceeded 45 g/m2.7 in women or 49 g/m2.7 in men. Hypertrophy was termed eccentric or concentric on the basis of the presence of normal (<0.43) or increased (≥0.43) relative wall thickness (2xPWTd/LVIDd), respectively. LV systolic function was evaluated by ejection fraction with the Teichholz correction21 and fractional shortening. Stroke volume was calculated by multiplying the time velocity integral of flow at the aortic annulus by its cross-sectional area.

Carotid atherosclerosis was evaluated with ultrasonography of the right and left common, internal, and external carotid arteries using a standardized protocol.12,22 Multiple projections were used to identify the presence of atherosclerosis (plaque), which was defined as a focal protrusion >50% beyond the thickness of the surrounding wall. The end-diastolic intimal-medial thickness and minimum and maximum diameters of the common carotid arteries were measured from 2-dimensionally guided M-mode images during several cycles, and the values were averaged.

Measurement of Arterial Stiffness
Patients with SLE underwent assessment of arterial stiffness from pressure-diameter relations of the common carotid artery and pressure waveforms obtained by applanation tonometry of the radial artery. A high-fidelity transducer was used with adjustment of orientation and pressure to achieve optimal applanation of the artery. Central arterial waveforms and pressures were calculated with the SphygmoCor device using a generalized transfer function (AtCor Medical, Sydney, Australia) and calibrated using the brachial mean and diastolic pressures. Applanation tonometry has been shown to yield accurate estimates of intra-arterial pulse pressure.23–25 Minimum (end-diastolic) and maximum (peak systolic) diameters were obtained from carotid ultrasonography performed immediately before applanation tonometry with the position of the subject and ambient environment unchanged. Arterial stiffness was estimated with the arterial stiffness index (ß): ln(Ps/Pd)/([Ds–Dd/Dd]), where Ps and Pd are aortic systolic and diastolic pressures, respectively, and Ds and Dd are carotid systolic and diastolic diameters, respectively. The arterial stiffness index has been shown to be a relatively pressure-independent measure of arterial stiffness.26

Laboratory Assessment
Patients with SLE underwent laboratory testing, including measurement of routine chemical analysis, including serum creatinine, total cholesterol and lipoprotein (a), measurement of serum complement C3 and C4, high-sensitivity C-reactive protein, and antibody testing, including double-stranded DNA, Smith, ribonuclear protein, Ro, La, and antiphospholipid antibodies (positive if level of either anticardiolipin IgG or IgM exceeded 40 isotype phospholipid units per milliliter or if lupus anticoagulant was present27). Serum interleukin-6 and tumor necrosis factor p55 and p75 receptors were measured with the use of kits (BioSource International, Carlsbad, Calif). Soluble intracellular adhesion molecule-1 and vascular adhesion molecule-1 were measured with an ELISA. Fasting homocysteine levels were obtained before and after the oral administration of methionine.28 CD40 ligand was measured as previously described.29

Statistical Analyses
Comparisons between SLE patients and referent subjects and between patients with and those without LV hypertrophy were made by using 2-sample t tests for continuous variables and by {chi}2 analysis for categorical variables. Results of continuous variables are presented as mean±SD unless otherwise stated. Comparisons between groups subdivided according to blood pressure and disease status were performed using ANOVA with post hoc testing for multiple comparisons. Bivariate relationships with LV mass were assessed using the Pearson correlation coefficient. All variables that had significant bivariate relations (as defined by P<0.05) with the outcome were evaluated for inclusion in a model predicting LV mass using multivariable regression analysis; unstandardized regression coefficients (B) with their 95% confidence intervals are reported. Two-sided values of P<0.05 were considered to indicate statistical significance.

The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Description of SLE Patients
Among the 173 SLE patients included in the present study, prevalences of SLE diagnostic criteria were as follows: malar rash (45%), discoid rash (8%), photosensitivity (33%), oral ulcers (24%), arthritis (91%), serositis (45%), renal disorder (34%), neurological disorder (15%), and hematological disorder (54%). In addition, anti-DNA antibodies were present in 43%, anti-Smith in 11%, anti–ribonuclear protein in 27%, anti-La in 5%, anti-Ro in 41%, and antiphospholipid antibodies in 19%. The median Systemic Lupus Erythematosus Disease Activity Index was 2.0 (range, 0 to 22) and ≤4.0 in 68% at the time of study. Current or former use of prednisone was present in 90% of patients, whereas other immunosuppressive therapy was less common (azathioprine in 33%, cyclophosphamide in 20%, and methotrexate in 10%). Hydroxychloroquine had been used by 76% of patients; warfarin had been used by 15%. Lipid-lowering therapy had been used by only 5% of patients at the time of study.

Comparison of SLE Patients and Referent Subjects
By design, SLE patients and the reference group were matched for age and gender and did not differ in other traditional risk factors (Table 1). Mean systolic and diastolic blood pressures were higher in referent subjects, likely as a result of systematic withdrawal of antihypertensive medications. Similar to earlier findings, carotid atherosclerosis was detected much more frequently in the SLE patients. Likewise, carotid intimal-medial thickness was smaller and end-diastolic diameter was greater in the SLE patients, with overall slightly greater arterial mass (cross-sectional area) in the reference group. LV wall thicknesses, chamber dimensions, and mass were higher in SLE patients than in the reference group (Table 2), resulting in significantly higher LV mass and a higher prevalence of LV hypertrophy (all P<0.001). LV hypertrophy was eccentric in 29 of 31 SLE patients (93.5%) with hypertrophy and 7 of 11 referent subjects (63.6%) with hypertrophy. In addition, ejection fraction and cardiac output were higher in SLE patients (all P<0. 01). Left atrial and aortic dimensions also were significantly larger in SLE patients.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Characteristics of SLE Patients and the Reference Group


View this table:
[in this window]
[in a new window]

  		TABLE 2. Comparison of LV Structure and Function in SLE Patients and the Reference Group

In univariate analyses involving the entire sample (Table 3), significant correlates of LV mass index included age, body mass index (BMI), hypertension, diabetes mellitus, and presence of carotid atherosclerosis (all P<0.001). In multivariable regression analyses (Table 4), the presence of SLE (P<0.001), along with age, BMI, hypertension, and diabetes mellitus (all P<0.005), had positive associations with LV mass index.


View this table:
[in this window]
[in a new window]

  		TABLE 3. Individual Correlates of LV Mass Index Among Patients and the Reference Group


View this table:
[in this window]
[in a new window]

  		TABLE 4. Multivariable Determinants of LV Mass Index in the Entire Sample

Relation of LV Mass to Traditional Risk Factors and Disease Aspects in SLE Patients
Among patients with SLE, LV mass index was strongly related to higher blood pressure, body size, homocysteine concentration, and arterial stiffness (Table 5). In addition, LV mass index was significantly higher in the presence of diabetes (63.2±30.1 versus 37.0±8.5 g/ht2.7; P<0.001), hypertension (45.6±17.0 versus 35.8±7.5 g/ht2.7; P<0.001), and carotid atherosclerosis (41.0±15.5 versus 37.0±8.7 g/ht2.7; P=0.034). Current smoking was not associated with LV mass index (37.1±6.8 versus 38.4±11.6 g/ht2.7; P=0.54), nor was family history of premature cardiovascular disease (38.1±11.2 versus 38.6±11.0 g/ht2.7; P=0.85).


View this table:
[in this window]
[in a new window]

  		TABLE 5. Individual Correlates of LV Mass Index (g/m2.7) in SLE Patients

SLE disease characteristics related to LV mass index included duration of disease, the damage index, and circulating levels of intracellular adhesion molecule-1 and tumor necrosis factor p55 receptor. Renal involvement was not significantly related to the presence of LV hypertrophy (22% versus 16%; P=0.27) or to LV mass index (40.0±11.7 versus 37.5±11.5 g/m2.7; P=0.19). LV mass index was not related to the presence or absence of anti-DNA (37.8±11.9 versus 38.7±11.5 g/m2.7, respectively; P=0.60), anti-Smith (35.6±8.5 versus 38.7±12.0 g/m2.7; P=0.28), anti-Ro (39.2±14.2 versus 37.7±9.6 g/m2.7; P=0.43), anti-La (37.7±13.6 versus 38.4±11.6 g/m2.7; P=0.87), or anti-antiphospholipid (39.2±11.8 versus 38.1±11.6 g/m2.7; P=0.61) antibodies. In contrast, LV mass was significantly higher in patients who did not have anti–ribonuclear protein antibodies (39.5±12.6 versus 34.9±7.4 g/m2.7; P=0.023), likely because all SLE patients with diabetes mellitus and 73% of those with hypertension were negative for anti–ribonuclear protein. Current or former immunosuppressive therapy with prednisone, azathioprine, cyclophosphamide, and methotrexate was not related to LV mass index (data not shown). In multivariable analyses using those parameters significant in univariate analyses, higher arterial stiffness index and body mass index, as well as the presence of diabetes and hypertension, were all strong determinants of LV mass index (Table 6).


View this table:
[in this window]
[in a new window]

  		TABLE 6. Multivariable Determinants of LV Mass Index in SLE Patients

To further explore the extent to which arterial stiffness is related to traditional risk factors as opposed to disease-related factors, we examined bivariate relations of arterial stiffness to the variables listed in Table 5, as well as to pharmacological therapy, autoantibodies, and the presence of carotid atherosclerosis. Individual correlates of stiffness included age (or age at diagnosis), mean arterial pressure, diabetes, presence of carotid atherosclerosis (all P<0.001), SLE duration (P=0.005), and the Systemic Lupus International Collaborating Clinics Damage Index (P=0.022). In multivariable analyses, predictors of arterial stiffness were age at diagnosis, disease duration, diabetes (all P<0.001), and carotid atherosclerosis (P=0.023), whereas mean arterial pressure (P=0.079) and the damage index (P=0.16) were of borderline significance.

Relative Impacts of Hypertension and SLE on LV Hypertrophy
To understand better the extent to which SLE might augment the impact of hypertension, a potent stimulus to LV hypertrophy, the patient and reference groups were subdivided according to hypertension status. Among normotensive subjects, LV mass was strikingly increased in SLE patients compared with referent subjects independently of the method of expression (absolute LV mass, 134.7±28.5 versus 118.4±26.7 g; LV mass/body surface area, 77.4±12.9 versus 68.8±12.7 g/m2; LV mass/height2.7, 35.8±7.5 versus 31.4±6.5 g/ht2.7; all P<0.001). Similar findings were obtained in the hypertensive subset (absolute LV mass, 170.6±62.0 versus 118.4±26.7 g, P=0.049; LV mass/body surface area, 95.3±35.7 versus 81.5±15.7 g/m2, P=0.037; LV mass/height2.7, 45.6±17.0 versus 38.4±9.1 g/height2.7, P=0.017) in patients with and without SLE, respectively. LV mass index was lower in normotensive referent subjects than in the 3 other subgroups (P<0.005 for all). LV mass was increased in normotensive SLE patients to an extent comparable to that of hypertensive referent subjects. Furthermore, the presence of both SLE and hypertension resulted in a significant increase in LV mass beyond the presence of hypertension alone (the Figure). Consequently, although normotensive SLE patients and hypertensive referent subjects had comparable LV mass index (P=0.53), LV mass index was significantly higher in hypertensive SLE patients than in hypertensive subjects in the reference group (P=0.006).


Figure 1184932
View larger version (11K):
[in this window]
[in a new window]

  		Comparison of LV mass (indexed to height2.7) in normotensive (NL) and hypertensive (HTN) referent subjects and SLE patients. See text for subgroup comparisons.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
The present study demonstrates a significantly increased prevalence of LV hypertrophy in SLE patients compared with referent subjects with, on average, higher arterial pressure. Moreover, increases in LV mass index not only were related to the traditional stimuli of age, obesity (BMI), hypertension, and diabetes but also were associated with the presence of SLE per se. Thus, SLE, in addition to traditional stimuli, augments LV mass, especially in the setting of hypertension. These findings suggest a direct disease-related effect of SLE on LV structure. Our finding of arterial stiffness as a strong determinant of LV mass in SLE patients supports the hypothesis that inflammation-mediated vascular stiffening plays a significant role in LV structural changes in SLE. In addition, in the absence of clinical or echocardiographic evidence of coronary or significant valvular heart disease, systolic function was found to be preserved in SLE patients.

Although prior smaller studies have reported LV hypertrophy in SLE patients, these findings were either observational or confounded by concomitant valvular, cardiovascular, or renal disease. Cervera et al3 and Omdal et al4 reported LV hypertrophy in only 6 of 70 and 3 of 35 SLE patients, respectively, prevalences more comparable to those seen in our reference group, of whom 20% were hypertensive. Leung et al6 found significantly more LV hypertrophy in 75 SLE subjects compared with 60 control subjects when investigating the association of antiphospholipid antibodies with cardiac abnormalities. However, in that study, 48 patients were reported to have renal disease, and a total of 25 patients had mitral and/or aortic valve disease. In a more detailed study by Crozier et al,1 greater LV wall thicknesses and mass and lower ejection fractions were found in 50 SLE patients compared with control subjects; however, patients with valvular disease and pericardial effusion were included, and 14% of SLE patients and no control subjects had hypertension. In contrast, Fujimoto et al,2 in a study that excluded SLE patients with diabetes or ischemic and valvular heart disease, noted an increase in fractional shortening among SLE subjects compared with control subjects, consistent with the findings in the present study. The significantly greater end-diastolic yet comparable end-systolic dimensions found in SLE patients in our study suggest that increases in LV systolic performance result from the Starling phenomenon. Although other smaller studies have suggested a relation between LV systolic dysfunction and the presence of antiphospholipid antibodies,6,30 we did not detect such an association in our much larger sample.31

In addition to disease status, our findings show that age, BMI, hypertension, and diabetes mellitus contribute significantly to LV mass index, all of which are well-documented stimuli to LV hypertrophy.32–34 Other studies have attributed LV hypertrophy in SLE to the additional presence of hypertension.35–38 Our study documents that hypertension is not the primary cause of LV hypertrophy in SLE on the basis of comparable prevalences of hypertension in the patient and reference groups and on subgroup analyses in normotensive and hypertensive subjects demonstrating that the presence of both SLE and hypertension leads to increases in LV mass beyond the presence of hypertension alone. These findings are even more striking in that the diagnosis of hypertension may be less robust in SLE patients (ie, blood pressure may be primarily or exclusively elevated during flares, and antihypertensive medications were not discontinued for study purposes in SLE patients, whereas they were discontinued for weeks to months in our hypertensive referent subjects).

The associations of duration of disease, damage index, and higher levels of soluble intracellular adhesion molecule-1 and tumor necrosis factor p55 receptor with LV mass index in univariate analyses suggest that the duration and severity of the inflammatory state contribute to LV hypertrophy in SLE. Inflammatory mediators affect leukocytes, myocytes, and matrix and thereby contribute to remodeling and hypertrophy of the heart. Although these factors were not significant in multivariable analyses, we have previously demonstrated a marked increase in arterial stiffness in a subset of the SLE patients included in the present study versus age-matched control subjects (3.36±0.13 versus 2.60±0.13; P<0.001) that was associated with disease duration and circulating levels of C-reactive protein and interleukin-6,10 suggesting that arterial stiffening might summate the duration and severity of inflammation. Of note, use of immunosuppressive therapy was not related to LV mass, raising the possibility that nonspecific blockade of inflammatory mediators may not reestablish the balance necessary to remodel and restore the physical properties of large conduit arteries. Although subclinical myocarditis resulting from inflammation has been suggested as a possible mechanism for the increased incidence of heart failure among rheumatoid arthritis patients,39 myocarditis is unlikely to be the cause of LV hypertrophy among SLE patients in our study because myocarditis in lupus patients is marked by signs and symptoms of heart failure and echocardiographic evidence of depressed ejection fraction and wall motion abnormalities.40,41 Although LV mass index was significantly higher among SLE patients when carotid atherosclerosis was present, raising the possibility that subclinical coronary artery atherosclerosis might be the cause of LV hypertrophy among SLE patients, the presence of carotid atherosclerosis was not a determinant of LV mass index in multivariable analyses.

Limitations of our study include the lack of systematic assessment of LV diastolic filling parameters. Although abnormalities of diastolic filling have been reported in several small studies,2,42–46 among 131 SLE patients in our study with data on transmitral flow, deceleration time was prolonged in only 17 and isovolumic relaxation time was prolonged in only 2. Although newer techniques such as tissue Doppler imaging and strain rate may provide more specific detection of abnormal diastolic properties, no data exist to suggest such abnormalities might cause, rather than be a result of, an increase in LV mass. Another limitation is the single determination of inflammatory markers, which may not be an accurate representation of inflammatory burden over time. Although most hypertensive SLE patients were studied while taking antihypertensive medication, we believe the lack of antihypertensive medications in the hypertensive referent subjects would favor greater LV mass in this group, the opposite of our findings. In addition, the higher LV mass in normotensive SLE patients, despite slightly lower blood pressure (105±14/68±8 mm Hg in SLE patients versus 110±12/69±8 mm Hg in normotensive referent subjects; P=0.006 for systolic pressure), strongly argues in favor of SLE rather than blood pressure as the cause of increased LV mass.

Conclusions
SLE patients have an increased prevalence of LV hypertrophy that is not exclusively a result of concomitant coronary artery or valvular heart disease, renal involvement, premature subclinical atherosclerosis, or other traditional stimuli, including hypertension. Our results suggest that inflammation-mediated arterial stiffening, a strong determinant of LV hypertrophy, is likely the underlying mechanism for LV hypertrophy in SLE. LV hypertrophy is known to lead to increased risk of stroke, coronary artery disease, congestive heart failure, and sudden cardiac death in varied populations47–50 and therefore is likely to be a prognostic indicator of cardiac morbidity and mortality in SLE patients. Our findings suggest that more aggressive and targeted therapy may be needed to control the inflammation-mediated effects on vascular stiffening that lead to LV hypertrophy.


*    Acknowledgments
 
Sources of Funding

This work was supported by National Institutes of Health grants AR 45591 (National Institute of Arthritis and Musculoskeletal and Skin Diseases), HL47540 (National Heart, Lung, and Blood Institute), and M10RR0047 (Public Health Service Research Grant for the General Clinical Research Center).

Disclosures

None.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Crozier IG, Li E, Milne MJ, Nicholls GM. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol. 1990; 65: 1145–1148.[CrossRef][Medline] [Order article via Infotrieve]
  2. Fujimoto S, Kagoshima T, Nakajima T, Dohi K. Doppler echocardiographic assessment of left ventricular diastolic function in patients with systemic lupus erythematosus. Cardiology. 1994; 85: 267–272.[CrossRef][Medline] [Order article via Infotrieve]
  3. Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A, Ingelmo M. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis. 1992; 51: 156–159.[Abstract/Free Full Text]
  4. Omdal R, Lunde P, Rasmussen K, Mellgren SI, Husby G. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. Scand J Rheumatol. 2001; 30: 275–281.[CrossRef][Medline] [Order article via Infotrieve]
  5. Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S. Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a defined population. Medicine. 1992; 71: 216–223.[Medline] [Order article via Infotrieve]
  6. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med. 1990; 89: 411–419.[CrossRef][Medline] [Order article via Infotrieve]
  7. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced by corticosteroid therapy: a study of 36 necropsy patients. Am J Med. 1975; 58: 243–264.[CrossRef][Medline] [Order article via Infotrieve]
  8. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med. 1980; 69: 849–858.[Medline] [Order article via Infotrieve]
  9. Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol. 1999; 24: 1–56.[CrossRef][Medline] [Order article via Infotrieve]
  10. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shanker BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005; 46: 1–6.[Abstract/Free Full Text]
  11. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D’Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997; 145: 408–415.[Abstract/Free Full Text]
  12. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349: 2399–2406.[Abstract/Free Full Text]
  13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271–1277.[Medline] [Order article via Infotrieve]
  14. Schnall PL, Schwartz JE, Landsbergis PA, Warren K, Pickering TG. A longitudinal study of job strain and ambulatory blood pressure: results from a three-year follow-up. Psychosom Med. 1998; 60: 697–706.[Abstract/Free Full Text]
  15. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults [erratum appears in J Am Coll Cardiol. 1996;28:1642]. J Am Coll Cardiol. 1996; 28: 751–756[Abstract]
  16. Petri M, Buyon J, Skovron ML, Kim M. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures. Arthritis Rheum. 1998; 41 (suppl): S218. Abstract.
  17. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieris S, Hanley J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A. The development and initial validation of the Systemic Lupus Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39: 363–369.[Medline] [Order article via Infotrieve]
  18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, St John Sutton M, Stewart WJ. Recommendations for chamber quantification: a report form the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 1440–1463.[CrossRef][Medline] [Order article via Infotrieve]
  19. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB. Normalization for body size and the population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens. 2005; 18: 191–196.[CrossRef][Medline] [Order article via Infotrieve]
  20. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25: 1056–1062.[Abstract]
  21. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlation in the presence and absence of asynergy. Am J Cardiol. 1976; 37: 7–11.[CrossRef][Medline] [Order article via Infotrieve]
  22. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006; 19: 943–954.[CrossRef][Medline] [Order article via Infotrieve]
  23. Kelly R, Hayward C, Ganis J, Daley J, Avolio A, O’Rourke M. Noninvasive registration of the arterial pressure waveform using high-fidelity applanation tonometry. J Vasc Med Biol. 1989; 1: 142–149.
  24. Chen C-H, Ting CT, Nussbacher A, Nevo E, Kass DA, Pak P, Wang SP, Chang MS, Yin FC. Validation of carotid tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension. 1996; 27: 168–175.[Abstract/Free Full Text]
  25. O’Rourke MF, Nichols WW, Safar ME. Pulse waveform analysis and arterial stiffness: realism can replace evangelism and scepticism. J Hypertens. 2004; 22: 1633–1634.[CrossRef][Medline] [Order article via Infotrieve]
  26. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction: a noninvasive method to predict severity of coronary atherosclerosis. Circulation. 1989; 80: 78–86.[Abstract/Free Full Text]
  27. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shonfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295–306.[CrossRef][Medline] [Order article via Infotrieve]
  28. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993; 39: 1764–1779.[Abstract]
  29. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 1999; 42: 871–881.[CrossRef][Medline] [Order article via Infotrieve]
  30. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation. 1990; 82: 369–375.[Abstract/Free Full Text]
  31. Farzaneh-Far A, Roman MJ, Lockshin, MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006; 54: 3918–3925.[CrossRef][Medline] [Order article via Infotrieve]
  32. Zabalgoitia M, Noor Ur, Rahman S, Haley WE, Mercado R, Yunis C, Lucas C, Yarows S, Krause L, Amarena J. Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients <65 to ≥65 years of age. Am J Cardiol. 1998; 82: 604–608.[CrossRef][Medline] [Order article via Infotrieve]
  33. Gutgesell HP, Rembold CM. Growth of the human heart relative to body surface area. Am J Cardiol. 1990; 65: 662–668.[CrossRef][Medline] [Order article via Infotrieve]
  34. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000; 101: 2271–2276.[Abstract/Free Full Text]
  35. Doherty NE, Feldman G, Maurer G, Siegel RJ. Echocardiographic findings in systemic lupus erythematosus. Am J Cardiol. 1988; 61: 1144.[CrossRef][Medline] [Order article via Infotrieve]
  36. Gentile R, Lagana B, Tubani L, Casato M, Ferri GM, Fedele F. Assessment of echocardiographic abnormalities in patients with systemic lupus erythematosus: correlation with levels of antiphospholipid antibodies. Ital Heart J. 2000; 1: 487–492.[Medline] [Order article via Infotrieve]
  37. Falcao CA, Alves IC, Chahade WH, Branco Pinto Duarte AL, Lucena-Silva N. Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. Arq Bras Cardiol. 2002; 79: 285–291.[Medline] [Order article via Infotrieve]
  38. Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB. The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population. Am Heart J. 1993; 125: 1117–1122.[CrossRef][Medline] [Order article via Infotrieve]
  39. Crowson CS, Nicola PJ, Kremers HM, O’Fallen WM, Therneau TM, Jacobsen SJ, Ballman KV, Gabriel SE. How much of the increased incidence of heart failure in rheumatoid arthritis patients is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 2005; 52: 3039–3044.[CrossRef][Medline] [Order article via Infotrieve]
  40. Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005; 14: 827–831.[Abstract/Free Full Text]
  41. Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med. 2002; 113: 419–423.[CrossRef][Medline] [Order article via Infotrieve]
  42. Enomoto K, Kaji Y, Mayumi T, Tsuda Y, Kanaya S, Nagasawa K, Fujino T, Niho Y. Left ventricular function in patients with stable systemic lupus erythematosus. Jpn Heart J. 1991; 32: 445–453.[Medline] [Order article via Infotrieve]
  43. Murai K, Oku H, Takeuchi K, Kanayama Y, Inoue T, Takeda T. Alterations in myocardial systolic and diastolic function in patients with active systemic lupus erythematosus. Am Heart J. 1987; 113: 966–971.[CrossRef][Medline] [Order article via Infotrieve]
  44. Leung WH, Wong KL, Lau CH, Wong CK, Cheng CH, Tai YT. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. Am Heart J. 1990; 120: 82–87.[CrossRef][Medline] [Order article via Infotrieve]
  45. Sasson Z, Rasooly Y, Chow WC, Marshall S, Urowitz MB. Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol. 1992; 69: 1629–1634.[CrossRef][Medline] [Order article via Infotrieve]
  46. Kalke S, Balakrishanan, Mangat G, Mittal G, Kumar N, Joshi VR. Echocardiography in systemic lupus erythematosus. Lupus. 1998; 7: 540–544.[Abstract/Free Full Text]
  47. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561–1566.[Abstract]
  48. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998; 32: 1454–1459.[Abstract/Free Full Text]
  49. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991; 67: 295–299.[CrossRef][Medline] [Order article via Infotrieve]
  50. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986; 105: 173–178.[Medline] [Order article via Infotrieve]
 

CLINICAL PERSPECTIVE

Patients with systemic lupus erythematosus (SLE) develop premature cardiovascular disease independently of traditional risk factors. In addition, abnormalities of left ventricular (LV) structure and function have been reported in SLE patients, although the impact of concomitant coronary, valvular, and renal disease has not been taken into account. In the present study, we compared 173 SLE patients free of clinical or echocardiographic evidence of coronary artery disease, valvular heart disease, or renal failure with a comparable number of subjects from a reference sample. The presence of SLE strongly predicted increased LV mass but not LV systolic dysfunction. Increased LV mass was associated with arterial stiffness. We have previously reported a marked increase in arterial stiffness in patients with chronic inflammatory disease that is related to markers of inflammation. Insofar as LV hypertrophy is a potent marker of excess cardiovascular morbidity and mortality in other samples, this observation in SLE patients may indicate a subset of patients at increased risk. In addition, antiinflammatory therapy to control disease and to reduce arterial stiffening may be of benefit in reducing LV hypertrophy and thereby clinical cardiovascular disease.




This article has been cited by other articles:


Home page
 CirculationHome page
M. J. Roman and J. E. Salmon
Cardiovascular Manifestations of Rheumatologic Diseases
Circulation, November 13, 2007; 116(20): 2346 - 2355.
[Full Text] [PDF]

This Article
Free upon publication Free Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/4/419    most recent
CIRCULATIONAHA.106.673319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pieretti, J.
Right arrow Articles by Salmon, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pieretti, J.
Right arrow Articles by Salmon, J. E.
Related Collections
Right arrow Hypertrophy
Right arrow Echocardiography

Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.